The value of CT scanning

ERS Monograph

Volumn 2015, Issue 9781849840644, 2015, Pages 121-133

  Ash, Samuel Y ^a   Washko, George R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85043522163     PISSN: 2312508X     EISSN: 23125098     Source Type: Journal    
DOI: 10.1183/2312508X.10019214     Document Type: Article

References (72)

1. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370: 797–799.
2. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155–161.
3. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598–604.
4. Hayhurst MD, MacNee W, Flenley DC, et al. Diagnosis of pulmonary emphysema by computerised tomography. Lancet 1984; 2: 320–322.
5. Müller NL, Staples CA, Miller RR, et al. “Density mask”. An objective method to quantitate emphysema using computed tomography. Chest 1988; 94: 782–787.
6. Stockley RA, Parr DG, Piitulainen E, et al. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010; 11: 136.
7. Coxson HO, Dirksen A, Edwards LD, et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med 2013; 1: 129–136.
8. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059–2073.
9. Sciurba FC, Ernst A, Herth FJ, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 2010; 363: 1233–1244.
10. Herth FJ, Noppen M, Valipour A, et al. Efficacy predictors of lung volume reduction with zephyr valves in a European cohort. Eur Respir J 2012; 39: 1334–1342.
11. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355–1360.
12. Nakano Y, Wong JC, de Jong PA, et al. The prediction of small airway dimensions using computed tomography. Am J Respir Crit Care Med 2005; 171: 142–146.
13. Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 2000; 162: 1102–1108.
14. Hasegawa M, Nasuhara Y, Onodera Y, et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 1309–1315.
15. Han MK, Kazerooni EA, Lynch DA, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology 2011; 261: 274–282.
16. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011; 365: 1567–1575.
17. Kim V, Desai P, Newell JD, et al. Airway wall thickness is increased in COPD patients with bronchodilator responsiveness. Respir Res 2014; 15: 84.
18. Diaz AA, Come CE, Ross JC, et al. Association between airway caliber changes with lung inflation and emphysema assessed by volumetric CT scan in subjects with COPD. Chest 2012; 141: 736–744.
19. Washko GR, Diaz AA, Kim V, et al. Computed tomographic measures of airway morphology in smokers and never-smoking normals. J Appl Physiol 2014; 116: 668–673.
20. Martinez-Garcia MA, de la Rosa Carrillo D, Soler-Cataluna JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 823–831.
21. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 400–407.
22. Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 549–555.
23. Falk JA, Kadiev S, Criner GJ, et al. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 543–548.
24. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371–1385.
25. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management. Chest 2010; 137: 39S–51S.
26. Scarrow GD. The pulmonary angiogram in chronic bronchitis and emphysema. Proc R Soc Med 1965; 58: 684–687.
27. Jacobson G, Turner AF, Balchum OJ, et al. Vascular changes in pulmonary emphysema. The radiologic evaluation by selective and peripheral pulmonary wedge angiography. Am J Roentgenol Radium Ther Nucl Med 1967; 100: 374–396.
28. Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012; 367: 913–921.
29. Regan EA, Hokanson JR, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010; 7: 32–43.
30. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008; 31: 869–873.
31. Estépar RS, Kinney GL, Black-Shinn JL, et al. Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications. Am J Respir Crit Care Med 2013; 188: 231–239.
32. Schols AM. Pulmonary cachexia. Int J Cardiol 2002; 85: 101–110.
33. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J 2008; 31: 492–501.
34. Congleton J. The pulmonary cachexia syndrome: aspects of energy balance. Proc Nutr Soc 1999; 58: 321–328.
35. Sergi G, Coin A, Marin S, et al. Body composition and resting energy expenditure in elderly male patients with chronic obstructive pulmonary disease. Respir Med 2006; 100: 1918–1924.
36. Richardson RS, Sheldon J, Poole DC, et al. Evidence of skeletal muscle metabolic reserve during whole body exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 881–885.
37. Budweiser S, Heinemann F, Meyer K, et al. Weight gain in cachectic COPD patients receiving noninvasive positive-pressure ventilation. Respir Care 2006; 51: 126–132.
38. Femia RA, Goyette RE. The science of megestrol acetate delivery: potential to improve outcomes in cachexia. BioDrugs 2005; 19: 179–187.
39. Takabatake N, Nakamura H, Abe S, et al. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1215–1219.
40. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1179–1184.
41. Lewis MI. Apoptosis as a potential mechanism of muscle cachexia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 434–436.
42. Andreas S, Anker SD, Scanlon PD, et al. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 2005; 128: 3618–3624.
43. Langen RC, Schols AM, Kelders MC, et al. Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. Am J Respir Cell Mol Biol 2006; 35: 689–696.
44. Van Helvoort HA, Heijdra YF, Thijs HM, et al. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc 2006; 38: 1543–1552.
45. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1414–1418.
46. Baumgartner RN, Stauber PM, McHugh D, et al. Cross-sectional age differences in body composition in persons 60+ years of age. J Gerontol A Biol Sci Med Sci 1995; 50: M307–M316.
47. Kehayias JJ, Fiatarone MA, Zhuang H, et al. Total body potassium and body fat: relevance to aging. Am J Clin Nutr 1997; 66: 904–910.
48. Zamboni M, Armellini F, Harris T, et al. Effects of age on body fat distribution and cardiovascular risk factors in women. Am J Clin Nutr 1997; 66: 111–115.
49. Forbes GB. Longitudinal changes in adult fat-free mass: Influence of body weight. Am J Clin Nutr 1999; 70: 1025–1031.
50. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the health, aging and body composition study. Am J Clin Nutr 2005; 82: 872–878.
51. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 809–813.
52. Díaz AA, Morales A, Díaz JC, et al. CT and physiologic determinants of dyspnea and exercise capacity during the six-minute walk test in mild COPD. Respir Med 2013; 107: 570–579.
53. McDonald ML, Diaz AA, Ross JC, et al. Quantitative computed tomography measures of pectoralis muscle area and disease severity in chronic obstructive pulmonary disease. A cross-sectional study. Ann Am Thorac Soc 2014; 11: 326–334.
54. Lehouck A, Boonen S, Decramer M, et al. COPD, bone metabolism, and osteoporosis. Chest 2011; 139: 648–657.
55. Budoff MJ, Hamirani YS, Gao YL, et al. Measurement of thoracic bone mineral density with quantitative CT. Radiology 2010; 257: 434–440.
56. Camilli AE, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991; 133: 795–800.
57. Gunes Y, Tuncer M, Guntekin U, et al. Reliability of symptoms suggestive of angina in patients with chronic obstructive pulmonary disease. Arq Bras Cardiol 2009; 92: 334–338.
58. Brekke PH, Omland T, Smith P, et al. Underdiagnosis of myocardial infarction in COPD-cardiac infarction injury score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008; 102: 1243–1247.
59. O’Malley PG, Taylor AJ, Jackson JL, et al. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. Am J Cardiol 2000; 85: 945–948.
60. Budoff MJ, Nasir K, Kinney GL, et al. Coronary artery and thoracic calcium on noncontrast thoracic CT scans: comparison of ungated and gated examinations in patients from the COPD gene cohort. J Cardiovasc Comput Tomogr 2011; 5: 113–118.
61. Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax 2014; 69: 718–723.
62. Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008; 63: 301–305.
63. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008; 178: 738–744.
64. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395–409.
65. Sanchez-Salcedo P, Wilson DO, de-Torres JP, et al. Improving selection criteria for lung cancer screening. The potential role of emphysema. Am J Respir Crit Care Med 2015; 191: 924–931.
66. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277–2284.
67. Church TR, Black WC, Aberle DR, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013; 368: 1980–1991.
68. Ley-Zaporozhan J, Ley S, Kauczor HU. Proton MRI in COPD. COPD 2007; 4: 55–65.
69. Vogel-Claussen J, Renne J, Hinrichs J, et al. Quantification of pulmonary inflammation after segmental allergen challenge using turbo-inversion recovery-magnitude magnetic resonance imaging. Am J Respir Crit Care Med 2014; 189: 650–657.
70. Subramanian DR, Jenkins L, Edgar R, et al. Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography. Am J Respir Crit Care Med 2012; 186: 1125–1132.
71. Coxson HO, Quiney B, Sin DD, et al. Airway wall thickness assessed using computed tomography and optical coherence tomography. Am J Respir Crit Care Med 2008; 177: 1201–1206.
72. Coxson HO, Leipsic J, Parraga G, et al. Using pulmonary imaging to move chronic obstructive pulmonary disease beyond FEV1. Am J Respir Crit Care Med 2014; 190: 135–144.